#irritable-bowel-syndrome-drugs-market-share

[trendsofmarket]

Analysis of Irritable Bowel Syndrome (IBS) Treatment Market Research By Production, Revenue, Growth Rate, Sales Value, Industry Trends, Impact Factors, SWOT Analysis

Research Nester assesses the growth and size of the global irritable bowel syndrome (IBS) treatment market, which is anticipated to be driven by rising advancements in drug development.

Research Nester’s recent market research analysis on “irritable bowel syndrome (IBS) Treatment Market: Global Demand Analysis & Opportunity Outlook 2037” delivers a detailed competitors analysis and overview of the global irritable bowel syndrome (IBS) treatment market in terms of market segmentation by condition, drug class, dosage form, distribution channel, and by region.

Request Report Sample@

Increasing Prevalence of Irritable Bowel Syndrome to Drive Market Growth

The rising prevalence of irritable bowel syndrome issues across the world is the prime factor fuelling the market growth. For instance, according to the analysis by the International Foundation for Gastrointestinal Disorders (IFFGD), the prevalence rate of irritable bowel syndrome is around 5% to 10% globally. Stressful lifestyles and poor dietary habits are leading to irritable bowel syndrome issues among the population, driving the need for effective medications.

The growing population of senior citizens is also positively influencing the sales of irritable bowel syndrome medications. The geriatric population is more susceptible to irritable bowel syndrome, contributing to a larger patient base and high market demand.

Growth Drivers:

Increasing IBS awareness programs by public and private organizations

Rising popularity of digital health solutions and services

Challenges

The introduction of advanced irritable bowel syndrome medications requires high investments in research and development activities, which increases the overall product costs. The high costs of new therapies can be prohibitive for patients with low earning power and healthcare facilities in poor economies.

The strict and complex drug approval procedures may limit the sales of irritable bowel syndrome medications to some extent.  Prolonged approval processes are significantly hampering the profits of irritable bowel syndrome drug producers.

Access our detailed report at:

Based on dosage form, the tablets segment is expected to hold a significant market share of 68.2% through 2037. The convenience and accurate dosage are primarily increasingly appealing tablets among target patients. The sales of irritable bowel syndrome tablets are foreseen to increase at a CAGR of 8.6% from 2025 to 2037.

By region, North America leads the sales of irritable bowel syndrome medications and is estimated to capture 36.4% of the revenue share by 2037. The presence of advanced healthcare facilities, research and treatment organizations, and industry giants is augmenting the irritable bowel syndrome (IBS) treatment market growth in the region.

Request for customization @

This report also provides the existing competitive scenario of some of the key players of the global irritable bowel syndrome (IBS) treatment market which includes company profiling of Teva Pharmaceutical Industries Ltd., Abbott Laboratories, Bausch Health Companies Inc., Bayer AG, Ironwood Pharmaceuticals, Inc., Johnson & Johnson, Sanofi S.A., Sebela Pharmaceuticals Inc., Novartis AG, Validus Pharmaceuticals LLC, AstraZeneca Plc, and GlaxoSmithKline, Plc.

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates, and executives to make wise decisions for their future marketing strategy, expansion investment, etc. We believe every business can expand to its new horizon, provided the right guidance at the right time is available through strategic minds. Our out-of-the-box thinking helps our clients to make wise decisions to avoid future uncertainties.

Contact for more Info:

AJ Daniel

Email: info@researchnester.com

U.S. Phone: +1 646 586 9123

[marketsndata]

Global Gastrointestinal Drugs Market Size, Share, Growth and Forecast 2031

Global gastrointestinal drugs market is projected to witness a CAGR of 4.23% during the forecast period 2024-2031, growing from USD 45.20 billion in 2023 to USD 62.96 billion in 2031. The market’s growth is boosted by the rising cases of gastrointestinal diseases, novel product launches by the market players, and increasing emphasis on ensuring the availability of gastrointestinal drugs in different regions across the globe.

Technological advancements in drug delivery mechanisms and formulations are enhancing the efficacy of gastrointestinal drugs. The advancements include the development of extended-release and delayed-release formulations that aid in improving the bioavailability and absorption of the drugs, resulting in improved patient outcomes. Such developments are revolutionizing the treatment of ulcerative colitis and Crohn’s disease, among others, providing lucrative growth opportunities for the market.

The rising prevalence of various gastrointestinal disorders, such as celiac disease, is also propelling the growth of the global gastrointestinal drugs market. According to an article published in the StatPearls journal of StatPearls Publishing LLC in August 2023, the prevalence of celiac disease is approximately 0.5% to 1% among the general population. Additionally, the number of cases of Crohn’s disease is also increasing at a rapid rate. According to the estimates of the National Institute of Diabetes and Digestive and Kidney Diseases, more than half a million people are suffering from Crohn’s disease in the United States. Thus, various pharmaceutical companies are investing in research activities to augment the development of novel therapies to combat the growing threat of Crohn’s disease. In October 2023, Eli Lilly and Company announced that the investigational interleukin-23p19 antagonist, mirikizumab met all major secondary and co-primary endpoints in a phase 3 study, evaluating its efficacy and safety for treating adults with severely to moderately active Crohn’s disease. 

Increasing Cases of Gastrointestinal Diseases Boost Market Demand

The rising cases of gastrointestinal distress in various regions across the globe due to changes in lifestyle and eating habits of the population is one of the major factors bolstering the global gastrointestinal drugs market demand. Factors such as increased stress and the rising prevalence of obesity are also propelling the incidences of gastrointestinal diseases. According to the estimates of the World Health Organization (WHO), 1 in 8 people around the world were living with obesity in 2022. This increase is augmenting the incidences of diseases such as peptic ulcers, irritable bowel syndrome, and gastroesophageal reflux disease. Furthermore, the rapid expansion of the aging population is also boosting the demand for gastrointestinal drugs as the older population is more susceptible to gastrointestinal issues. The WHO estimates that approximately 1 in 6 people across the globe will be 60 or older by 2030. Due to the rising occurrences of such issues, pharmaceutical companies are also increasingly focusing on developing innovative therapies that address the underlying cause of the disease rather than alleviating symptoms.

Rising Efforts of Pharma Companies Supports Market Expansion

The rising efforts of the key players in the market to ensure the availability of novel gastrointestinal drugs through investments and partnerships is boosting the global gastrointestinal drugs market size. In June 2024, AbbVie Inc. secured its position in the gastrointestinal drugs market by paying USD 150 million to China-based FutureGen Biopharmaceutical (Beijing) Co., Ltd. in near-term fees for rights to antibody drug targeting TL1A molecule that has been linked with a heightened immune response in cases of inflammatory bowel disease.

Similarly, in June 2024, Akum Drugs and Pharmaceuticals Ltd. unveiled new formulations for gastrointestinal diseases for patients in India. The company’s Rabeprazole + Levosulpiride SR Capsules received approval from the Drug Controller General of India (DCGI). The drugs aim to provide relief to patients suffering from gastrointestinal tract disorders. Rabeprazole sodium, a potent antisecretory compound, has demonstrated efficacy in treating duodenal and gastric ulcers along with gastroesophageal reflux disease by selectively inhibiting the secretion of gastric acid. Such efforts are expected to aid patients suffering from gastrointestinal issues in effectively managing their conditions and provide lucrative growth opportunities to the gastrointestinal drug market. 

Retail Pharmacies Hold Significant Market Share

The segment’s expansion can be attributed to the rising requirement for over-the-counter (OTC) gastrointestinal drugs over the past few years due to the rising cases of gastrointestinal distress and consumer preference for immediate relief from common digestive issues, including constipation, acid reflux, diarrhea, and heartburn. As per the American College of Gastroenterology (ACG) estimates, approximately 20% of the population of the United States suffers from gastroesophageal reflux disease. Due to the widespread presence of retail pharmacies and their convenient nature, patients suffering from gastrointestinal issues prefer them for purchasing medication, especially in semi-urban and urban locations.

Meanwhile, online pharmacies are expected to grow rapidly over the next few years due to the growing preference for online shopping, fast delivery, shipping, and the availability of lucrative discounts. Other advantages online pharmacies offer include increased consumer accessibility to a broad range of products. Additionally, the growing popularity of digital consultation and the rising availability of e-prescriptions have also made it easier for patients to avail themselves of the required medications through online pharmacies, bolstering the segment’s growth. 

North America Holds Major Market Share

The growth of the North American gastrointestinal drugs market can be attributed to the increasing efforts of the leading market players based in the region to ensure novel product launches, rising cases of gastrointestinal diseases, and the presence of well-established healthcare and pharmaceutical sectors. Various gastrointestinal diseases, including ulcerative colitis, Crohn’s disease, and inflammatory bowel disease, are becoming increasingly prevalent in the United States, bolstering the market’s demand. As per the estimates of the US Centers for Disease Control and Prevention, the prevalence of inflammatory bowel disease is between 2.4 and 3.1 million in the United States, with differing burdens across groups. Additionally, the prominent presence of various research organizations that are increasingly focusing on investigating different gastrointestinal diseases is also expected to influence the market’s expansion positively. Moreover, the increasing availability of novel drugs due to the increasing provision of approvals by the regulatory bodies in the region is also supporting the market’s growth is the region. In 2023, the US Food and Drug Administration (FDA) provided approval to five new gastrointestinal targeted drugs, including colonoscopy prep, inflammatory bowel disease, and gastroesophageal reflux disease. Such approvals are expected to increase the influx of various gastrointestinal drugs in North America.

Download Free Sample Report

Future Market Scenario (2024-2031F)

As per the global gastrointestinal drugs market analysis, the market is expected to witness significant growth in the coming years due to the growing burden of different gastrointestinal diseases and the increasing efforts of the market players towards novel product launches. According to an article published in January 2024 in the Dovepress of the Dove Medical Press Ltd, the prevalence of Crohn’s disease is expected to increase to 1% in 2030 in Western European countries and the United States. This increase will bolster the market’s demand to meet the growing drug requirement for effective management and treatment of the condition. The cases of gastrointestinal distress are also expected to increase in the coming years due to the increasing preference for fast foods and dining out as a fast food-filled diet lacks essential fiber intake, resulting in decreased adoption of water.

Additionally, the market is also expected to witness significant growth over the forecast period due to the rising investments by the leading pharmaceutical companies towards research and development activities and the emphasis on creating targeted therapies that provide minimal side effects along with long-term relief. Furthermore, the growing efforts of various countries to enhance their healthcare sectors and ensure the availability of necessary therapies and treatment solutions are further expected to propel the global gastrointestinal drugs market growth. 

Report Scope

“Gastrointestinal Drugs Market Assessment, Opportunities and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global gastrointestinal drugs market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.

Click here for full report- https://www.marketsandata.com/industry-reports/gastrointestinal-drugs-market

Latest reports-

Contact

Mr. Vivek Gupta 5741 Cleveland street, Suite 120, VA beach, VA, USA 23462 Tel: +1 (757) 343–3258 Email: info@marketsandata.com Website: https://www.marketsandata.com

[harshnews]

Functional Bowel Disorder Agents Market Size, Share, Demand, Future Growth, Challenges and Competitive Analysis

"Functional Bowel Disorder Agents Market – Industry Trends and Forecast to 2029

Global Functional Bowel Disorder Agents Market, By Drug Class (Anticholinergics, Chloride Channel Activators, Guanylate Cyclase-C Agonists, NHE3 Inhibitors, Peripheral Opioid Receptor Antagonists, Peripheral Opioid Receptor Mixed Agonists/Antagonists, Serotoninergic Neuroenteric Modulators), Application (Irritable Bowel Syndrome, Chronic Bloating, Diarrhea, Constipation, Others), Dosage (Injection, Tablet, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

Access Full 350 Pages PDF Report @

**Segments**

- By Drug Type: Laxatives, Antidiarrheal Agents, Antispasmodics, Others - By Disease Type: Irritable Bowel Syndrome (IBS), Functional Constipation, Functional Diarrhea, Others - By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

The market for functional bowel disorder agents is segmented by drug type, disease type, and distribution channel. In terms of drug type, the market is divided into laxatives, antidiarrheal agents, antispasmodics, and others. Laxatives are commonly used to treat constipation, antidiarrheal agents for diarrhea, and antispasmodics for abdominal pain and cramping associated with bowel disorders. The disease type segment includes irritable bowel syndrome (IBS), functional constipation, functional diarrhea, and others. IBS is a common disorder affecting the large intestine, leading to symptoms like cramping, abdominal pain, bloating, gas, diarrhea, and constipation. Functional constipation and diarrhea are conditions where bowel movements are not smooth and regular. Distribution channels for these agents include hospital pharmacies, retail pharmacies, and online pharmacies, providing accessibility to a wide range of consumers.

**Market Players**

- Allergan - Takeda Pharmaceutical Company Limited - Astellas Pharma Inc. - GlaxoSmithKline plc - AstraZeneca - Bayer AG - Sebela Pharmaceuticals Inc. - Takeda Pharmaceuticals U.S.A., Inc. - Sucampo Pharmaceuticals (U.S.) - Ironwood Pharmaceuticals, Inc.

Key market players in the functional bowel disorder agents market include Allergan, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., GlaxoSmithKline plc, AstraZeneca, Bayer AG, Sebela Pharmaceuticals Inc., Takeda Pharmaceuticals U.S.A., Inc., Sucampo Pharmaceuticals (U.S.), and Ironwood Pharmaceuticals, Inc.The market for functional bowel disorder agents is highly competitive, with key players striving to gain a significant market share through product innovation, strategic partnerships, mergers, acquisitions, and geographical expansion. Allergan is a prominent player with a diverse portfolio of gastrointestinal products, including treatments for irritable bowel syndrome and constipation. Takeda Pharmaceutical Company Limited focuses on research and development to introduce novel therapies for functional bowel disorders. Astellas Pharma Inc. has a strong presence in the market, offering a range of antispasmodic agents for managing symptoms associated with bowel disorders.

GlaxoSmithKline plc and AstraZeneca are global pharmaceutical giants that have made significant investments in developing and commercializing medications for gastrointestinal conditions. Bayer AG is known for its expertise in healthcare and offers a wide range of products for gastrointestinal disorders. Sebela Pharmaceuticals Inc. specializes in gastrointestinal therapies and has a dedicated focus on providing effective solutions for functional bowel disorders. Takeda Pharmaceuticals U.S.A., Inc. is a subsidiary of Takeda Pharmaceutical Company Limited and plays a vital role in marketing and distributing gastrointestinal products in the U.S. market.

Sucampo Pharmaceuticals (U.S.) is known for its research in gastrointestinal diseases and has brought forth innovative treatment options for functional bowel disorders. Ironwood Pharmaceuticals, Inc. is a key player that has developed multiple medications for various gastrointestinal conditions, contributing to the overall growth of the market. These market players compete on the basis of product quality, efficacy, safety, pricing, and distribution channels to cater to the diverse needs of patients suffering from functional bowel disorders.

The functional bowel disorder agents market is driven by factors such as the increasing prevalence of gastrointestinal diseases, changing dietary habits, sedentary lifestyles, and the rising awareness among consumers about treatment options. Market players are focusing on expanding their product portfolios, conducting clinical trials, and collaborating with healthcare providers to enhance patient outcomes. Moreover, the growing geriatric population, who are more prone to gastrointestinal issues, is also driving the demand**Global Functional Bowel Disorder Agents Market, By Drug Class** - Anticholinergics - Chloride Channel Activators - Guanylate Cyclase-C Agonists - NHE3 Inhibitors - Peripheral Opioid Receptor Antagonists - Peripheral Opioid Receptor Mixed Agonists/Antagonists - Serotoninergic Neuroenteric Modulators

The global functional bowel disorder agents market is witnessing significant growth driven by various factors. The market segmentation by drug class includes a wide range of medications such as anticholinergics, chloride channel activators, guanylate cyclase-C agonists, NHE3 inhibitors, peripheral opioid receptor antagonists, peripheral opioid receptor mixed agonists/antagonists, and serotoninergic neuroenteric modulators. This diverse range of drug classes allows healthcare providers to address different symptoms and conditions associated with functional bowel disorders effectively. The application segment encompasses irritable bowel syndrome, chronic bloating, diarrhea, constipation, and others, reflecting the broad spectrum of conditions that these agents can target. The dosage forms include injections, tablets, and others, providing flexibility in treatment options for patients. Moreover, the route of administration includes oral, intravenous, and others, offering various options for healthcare providers to administer medications based on patient needs.

In terms of end-users, hospitals, specialty clinics, homecare settings, and others play a crucial role in ensuring access to these medications for patients suffering from functional bowel

Functional Bowel Disorder Agents Key Benefits over Global Competitors:

The report provides a qualitative and quantitative analysis of the Functional Bowel Disorder Agents Market trends, forecasts, and market size to determine new opportunities.

Porter’s Five Forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make strategic business decisions and determine the level of competition in the industry.

Top impacting factors & major investment pockets are highlighted in the research.

The major countries in each region are analyzed and their revenue contribution is mentioned.

The market player positioning segment provides an understanding of the current position of the market players active in the Personal Care Ingredients

Table of Contents: Functional Bowel Disorder Agents Market

1 Introduction

2 Global Functional Bowel Disorder Agents Market Segmentation

3 Executive Summary

4 Premium Insight

5 Market Overview

6 Functional Bowel Disorder Agents Market, by Product Type

7 Functional Bowel Disorder Agents Market, by Modality

8 Functional Bowel Disorder Agents Market, by Type

9 Functional Bowel Disorder Agents Market, by Mode

10 Functional Bowel Disorder Agents Market, by End User

12 Functional Bowel Disorder Agents Market, by Geography

12 Functional Bowel Disorder Agents Market, Company Landscape

13 Swot Analysis

14 Company Profiles

Critical Insights Related to the Keyword Included in the Report:

Exclusive graphics and Illustrative Porter’s Five Forces analysis of some of the leading companies in this market

Value chain analysis of prominent players in the market

Current trends influencing the dynamics of this market across various geographies

Recent mergers, acquisitions, collaborations, and partnerships

Revenue growth of this industry over the forecast period

Marketing strategy study and growth trends

Growth-driven factor analysis

Emerging recess segments and region-wise market

An empirical evaluation of the curve of this market

Ancient, Present, and Probable scope of the market from both prospect value and volume

Browse Trending Reports:

Asia Pacific Mainframe Market

Asia Pacific Menstrual Cramps Treatment Market

Europe Commercial Cleaning Equipment Market

Europe Mainframe Market

Europe Quantum Computing Market

Europe Tomatoes Market

Europe Utility Locator Market

India Blood Gas Analyzer Market

Middle East And Africa Commercial Cleaning Equipment Market

Middle East And Africa Neurosurgery Market

Middle East And Africa Sports Medicine Market

Middle East And Africa Vaccines Market

Nigeria Cassava Starch Market

Nigeria Starch Processing Market

North America Menstrual Cramps Treatment Market

North America Neurosurgery Market

West Africa Baby Food Market

Antenna Market

Baby Apparel Market

Cassava Starch Market

Castor Oil Market

Cenospheres Market

Coconut Water Market

Collagen Casings Market

Facility Management Market

Functional Confectionery Market

Hemp Seed Market

Infrared Imaging Market

Instant Noodles Market

Laundry Detergents Market

Menstrual Cramps Treatment Market

Micro And Nano Plc Market

Motorcycle Market

Neurosurgery Market

Nickel Alloy Market

Over The Counter Probiotic Supplements Market

Polycystic Kidney Disease Adpkd Market

Private Label Food And Beverage Market

Recreational Cannabis Market

Tofu And Tempeh Market

Tomatoes Market

Vaccines Market

Varnish Makers Market

Wireless Medical Device Connectivity Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: corporatesales@databridgemarketresearch.com"

[health-views-updates]

Microbiome Therapeutics Market: Regional Dynamics and Emerging Opportunities

The global Microbiome Therapeutics Market Revenue, valued at USD 132.94 million in 2023, is projected to experience unprecedented growth, reaching USD 1,979.94 million by 2031. This expansion represents a compound annual growth rate (CAGR) of 40.16% over the forecast period from 2024 to 2031. The anticipated surge in market size reflects the increasing interest in microbiome-based therapies as a promising approach to treating a range of chronic and infectious diseases.

Microbiome therapeutics involve the development of therapies that leverage the beneficial properties of the microbiota — the collection of microorganisms residing in the human body — to treat or prevent various health conditions. The rapidly evolving understanding of the microbiome's role in health and disease has driven innovation in this field, leading to the development of novel therapeutic products that can restore the balance of the gut microbiota or target specific pathogens.

Key Market Dynamics and Drivers

The robust growth of the Microbiome Therapeutics Market is primarily driven by the increasing prevalence of chronic diseases, such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and metabolic disorders, along with the rising incidence of antibiotic-resistant infections. Microbiome-based therapies offer a new and innovative approach to addressing these conditions by modulating the gut microbiota, thereby improving patient outcomes and reducing dependency on conventional treatments.

Furthermore, the growing body of research supporting the role of the microbiome in immune modulation, metabolic regulation, and disease prevention has spurred investments in the development of microbiome-based drugs. Companies are increasingly focusing on microbiome therapeutics as a viable alternative to traditional pharmaceuticals, driving significant R&D activities and product development efforts in this space.

Get Free Smaple Report@ https://www.snsinsider.com/sample-request/2788 

Market Trends

The Microbiome Therapeutics Market is witnessing several key trends that are likely to propel its growth over the forecast period. These include:

Advancements in Microbiome Research: Significant progress in understanding the human microbiome's structure and function has led to the identification of specific microbial strains that can be harnessed for therapeutic purposes. This has opened new avenues for the development of targeted microbiome therapies, particularly for gastrointestinal, metabolic, and immune-related disorders.

Increased Investment in R&D: Pharmaceutical companies and biotech firms are making substantial investments in the development of microbiome-based drugs. Collaborations between academia, research institutions, and industry players are accelerating the discovery of new therapeutic candidates and the commercialization of microbiome products.

Rising Consumer Awareness: As consumers become more aware of the benefits of maintaining a healthy gut microbiome, there is an increasing demand for products that support microbiome health, including probiotics, prebiotics, and synbiotics. This trend is further driving interest in microbiome therapeutics.

Regulatory Support: Regulatory bodies in various countries are recognizing the potential of microbiome-based treatments and are providing frameworks for the approval and commercialization of these products. This support is expected to facilitate the entry of new players into the market and encourage the development of innovative therapies.

Regional Insights

North America held the largest share of the Microbiome Therapeutics Market in 2023, owing to its well-established healthcare infrastructure, high investment in R&D, and strong presence of key industry players. The region's focus on developing advanced therapies for chronic diseases and antibiotic-resistant infections has contributed to its leadership position in the market.

The Asia-Pacific region is expected to register the highest growth rate during the forecast period, driven by rising healthcare awareness, increasing prevalence of chronic conditions, and expanding investment in the life sciences sector. Countries such as China, Japan, and South Korea are at the forefront of microbiome research and are poised to play a crucial role in the market's growth.

Leading Companies in the Market

The Microbiome Therapeutics Market features a diverse range of players, from established pharmaceutical companies to emerging biotech firms. Some of the leading companies in this space include Seres Therapeutics, Vedanta Biosciences, Synlogic, Finch Therapeutics, and Evelo Biosciences. These companies are focusing on strategic collaborations, mergers, and acquisitions, as well as product innovation to enhance their market presence and cater to the growing demand for microbiome-based therapies.

Conclusion

The global Microbiome Therapeutics Market is set to witness exponential growth over the next decade, driven by increasing research, growing investment, and rising awareness of the microbiome's role in human health. As the demand for effective, targeted, and personalized treatments continues to rise, microbiome therapeutics are expected to emerge as a pivotal solution in the global healthcare landscape, offering new hope for patients with chronic and complex diseases.

[industryforecastnews]

Psyllium Market Size, Share & Business Outlook Report, 2030

Psyllium Market Growth & Trends

The global psyllium market size is estimated to reach USD 660.7 million in 2030 and is anticipated to expand at a CAGR of 9.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of chronic diseases such as diabetes, obesity, and gastrointestinal disorders has increased the demand for natural dietary fibers like psyllium. Consumers are increasingly adopting healthier lifestyles and seeking dietary supplements and functional foods that promote digestive health and weight management. Psyllium's soluble fiber content effectively aids in regulating bowel movements and lowering cholesterol levels, enhancing its appeal in dietary and pharmaceutical applications.

Regulatory approvals from health authorities such as the Food and Drug Administration (FDA) in the United States and European Food Safety Authority (EFSA) in Europe further validated the psyllium's health claims and safety for consumption. This regulatory support boosts consumer confidence and encourages manufacturers to incorporate psyllium into a wide range of products, including dietary supplements, pharmaceuticals, and functional foods, driving the market for psyllium during the forecast period.

Furthermore, the pharmaceutical and nutraceutical sectors represent substantial growth opportunities for the psyllium market. Psyllium is widely used as an active ingredient in laxatives, fiber supplements, and dietary fiber formulations due to its natural origin and regulatory approval for health claims related to digestive health. Manufacturers are innovating in product formulations to cater to specific health needs, such as products targeting irritable bowel syndrome (IBS) and constipation, further augmenting the growth and demand for psyllium during the forecast period.

Moreover, the global trend towards natural and plant-based ingredients in food and beverages has positively influenced the demand for psyllium. As consumers seek clean label products and healthier alternatives to synthetic ingredients, psyllium's natural origin and functional benefits make it an attractive ingredient for food formulators. Psyllium is used in a variety of food applications, including bakery products, cereals, snacks, and beverages, to enhance fiber content without compromising taste or texture. Manufacturers are responding to this trend by incorporating psyllium into new product formulations and promoting its nutritional benefits to meet consumer preferences for natural and sustainable food choices. This is expected to further drive the demand for the psyllium market during the forecast period.

Major players in the psyllium market include Satnam Psyllium Industries; Virdhara International; Premcem Gums Pvt. Ltd.; Jyotindra International; Abhyuday Industries; Shree Mahalaxmi Psyllium Pvt. Ltd.; Ispasen Remedies Private Limited; Rajganga Agro Product Pvt. Ltd.; Gayatri Psyllium Industries; Shubh Psyllium Industries; Psyllium Labs LLC; and Keyur Industries. Manufacturers are expanding their product portfolios to cater to diverse consumer preferences and industry requirements. This includes offering different forms of psyllium such as whole husk, husk powder, and psyllium seeds, each tailored for specific applications in pharmaceuticals, dietary supplements, functional foods, and beverages.

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/psyllium-market-report

Psyllium Market Report Highlights

North America is expected to grow with a CAGR of 10.5% over the forecast period from 2024 to 2030, driven by increasing consumer awareness of dietary fibers and the growing trend towards natural health supplements.

The psyllium husk powder market is expected to grow at a CAGR of 12.3% from 2024 to 2030. Psyllium powder is highly soluble and can be easily incorporated into various food products, beverages, and dietary supplements, making it a preferred choice for both consumers and manufacturers.

The organic psyllium market is expected to grow with a CAGR of 12.6% over the forecast period. Organic psyllium is cultivated without the use of synthetic pesticides or fertilizers, making it an attractive option for consumers seeking clean-label and environmentally friendly products, leading to increasing demand for organic psyllium.

Psyllium application in dietary supplements is expected to growth with a CAGR of 11.2% from 2024 to 2030. Psyllium is a rich source of soluble fiber, which helps regulate bowel movements, reduce cholesterol levels, and manage blood sugar levels, making it a popular ingredient in dietary supplements.

Psyllium Market Segmentation

Grand View Research has segmented the global psyllium market on the basis of product, nature, application, and region:

Psyllium Product Outlook (Revenue, USD Million, 2018 - 2030)

Psyllium Seeds

Whole Psyllium Husk

Psyllium Husk Powder

Psyllium Nature Outlook (Revenue, USD Million, 2018 - 2030)

Organic

Conventional

Psyllium Application Outlook (Revenue, USD Million, 2018 - 2030)

Food & Beverages

Dietary Supplements

Pharmaceuticals

Animal Feed

Others

Psyllium Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

Europe

Asia Pacific

Central & South America

Middle East & Africa

List of Key Players in Psyllium Market

Satnam Psyllium Industries

Virdhara International

Premcem Gums Pvt. Ltd.

Jyotindra International

Abhyuday Industries

Shree Mahalaxmi Psyllium Pvt. Ltd.

Ispasen Remedies Private Limited

Rajganga Agro Product Pvt. Ltd.

Gayatri Psyllium Industries

Shubh Psyllium Industries

Psyllium Labs LLC

Keyur Industries

Browse Full Report: https://www.grandviewresearch.com/industry-analysis/psyllium-market-report  

[naveendsw]

Irritable Bowel Syndrome Drugs Market Size, Share, Forecast

[industrynewsupdates]

Clinical Trials Market Size, Share, Growth and Industry Trends 2024 - 2030

The global clinical trials market size was valued at USD 80.7 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.49% from 2024 to 2030.  

The market growth spiked in 2020 owing to the COVID-19 pandemic. This growth pattern was witnessed by both virtual clinical trials and traditional ones. Several companies invested heavily in novel drug development to minimize COVID-19 patient burden. One such example being, in 2020, Synairgen plc and Parexel collaborated on a Phase III study of Interferon-beta (IFN-beta) treatment for COVID-19. Furthermore, rapid technological evolution, rising prevalence of chronic diseases, globalization of clinical trials, penetration of personalized medicine and a rise in demand for CROs for conducting research activities is expected to positively impact the market growth.

In addition, the COVID-19 pandemic led to changing the ways of conducting upcoming or ongoing clinical trials. Regulatory agencies including the U.S. FDA, the European Medicines Agency (EMA), the National Institutes of Health (NIH), and China’s National Medical Products Administration among several others issued various guidelines for conducting trials during the pandemic to support the implementation of decentralized clinical trials and virtual services. The current scenario for research and development activities across the globe and the need for several new treatment options have also led to the adoption of fast-track clinical trials. Thus, aforementioned factors are estimated to offer new avenues to the clinical trials market growth.

Gather more insights about the market drivers, restrains and growth of the Clinical Trials Market

Clinical Trials Market Report Highlights

• The phase III clinical trials segment dominated the market with a 53.3% share in 2023. This can be attributed to the complexity of this phase

• The interventional studies segment dominated the market in 2023. It is one of the most prominent methods used in clinical trials in the study design segment owing to the increasing demand for the intervention for clinical trials by researchers

• North America held 50.3% of the market share in 2023. Favorable government initiatives and the presence of a large number of players in the U.S. that offer advanced services are responsible for market growth

• Asia Pacific region is anticipated to grow at the fastest CAGR over the forecast period owing to the increasing patient pool and cost-efficient services.

Browse through Grand View Research's Healthcare IT Industry Research Reports.

• The global healthcare predictive analytics market size was estimated at USD 14.58 billion in 2023 and is projected to grow at a CAGR of 24.0% from 2024 to 2030.

• The global medical animation market size was valued at USD 396.2 million in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 20.1% from 2024 to 2030.

Clinical Trials Market Segmentation

Grand View Research has segmented the global clinical trials market based on phase, study design, indication, sponsor, indication by study design, and region:

Clinical Trials Phase Outlook (Revenue, USD Billion, 2018 - 2030)

• Phase I

• Phase II

• Phase III

• Phase IV

Clinical Trials Study Design Outlook (Revenue, USD Billion, 2018 - 2030)

• Interventional

• Observational

• Expanded Access

Clinical Trials Indication by Study Design Outlook (Revenue, USD Billion, 2018 - 2030)

• Autoimmune/Inflammation

o Rheumatoid Arthritis

o Multiple Sclerosis

o Osteoarthritis

o Irritable Bowel Syndrome (IBS)

o Others

• Pain Management

o Chronic Pain

o Acute Pain

• Oncology

o Blood Cancer

o Solid Tumors

o Other

• CNS Condition

o Epilepsy

o Parkinson's Disease (PD)

o Huntington's Disease

o Stroke

o Traumatic Brain Injury (TBI)

o Amyotrophic Lateral Sclerosis (ALS)

o Muscle Regeneration

o Others

• Diabetes

• Obesity

• Cardiovascular

• Others

Clinical Trials Indication Outlook (Revenue, USD Billion, 2018 - 2030)

• Autoimmune/Inflammation

o Interventional

o Observational

o Expanded Access

• Pain Management

o Interventional

o Observational

o Expanded Access

• Oncology

o Interventional

o Observational

o Expanded Access

• CNS Condition

o Interventional

o Observational

o Expanded Access

• Diabetes

o Interventional

o Observational

o Expanded Access

• Obesity

o Interventional

o Observational

o Expanded Access

• Cardiovascular

o Interventional

o Observational

o Expanded Access

• Others

o Interventional

o Observational

o Expanded Access

Clinical Trials Sponsor Outlook (Revenue, USD Billion, 2018 - 2030)

• Pharmaceutical & Biopharmaceutical Companies

• Medical Device Companies

• Others

Clinical Trials Service Type Outlook (Revenue, USD Billion, 2018 - 2030)

• Protocol Designing

• Site Identification

• Patient Recruitment

• Laboratory Services

• Bioanalytical Testing Services

• Clinical Trial Data Management Services

• Others

Clinical Trials Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o U.K.

o Germany

o France

o Spain

o Italy

• Asia Pacific

o India

o Japan

o China

o Australia

o South Korea

• Latin America

o Brazil

o Mexico

o Argentina

o Colombia

• Middle East & Africa

o South Africa

o Saudi Arabia

o UAE

Order a free sample PDF of the Clinical Trials Market Intelligence Study, published by Grand View Research.

[wellnessweb]

Impact of COVID-19 on the IBS Treatment Market Size

The Irritable Bowel Syndrome Treatment Market Size was valued at USD 1.47 billion in 2022, and is expected to reach USD 2.81 billion by 2030, and grow at a CAGR of 8.4% over the forecast period 2023-2030.In the realm of healthcare innovations, the Irritable Bowel Syndrome (IBS) treatment market stands as a frontier of continual evolution and advancement. As medical research unveils deeper insights into the complexities of gastrointestinal disorders, new therapies and interventions are emerging, promising relief and improved quality of life for patients worldwide. From traditional pharmaceuticals aimed at symptom management to groundbreaking probiotic formulations and personalized dietary approaches, the landscape of IBS treatment is marked by diversity and innovation. This dynamic market not only addresses the symptomatic aspects of IBS but also seeks to address underlying causes, aiming for holistic solutions that cater to individual patient needs.

The Irritable Bowel Syndrome Treatment Market  research report includes a comprehensive analysis, as well as an overview of the market segment, size, share, sectional analysis, and revenue forecasting. It considers market factors, industry trends, market dynamics, and the top competitors' strengths and weaknesses. There's additional information on distribution routes, traders, and dealers, as well as study findings and conclusions, an appendix, and data sources. The market research goes into considerable detail about product launch events, growth drivers, challenges, and investment potential.

Get Sample Of This Report @ https://www.snsinsider.com/sample-request/1774

Market Segmentation

By Type

IBS with Diarrhea (IBS-D)

Mixed-presentation IBS (IBS-M)

IBS with Constipation (IBS-C)

By Product

Eluxadoline

Lubiprostone

Rifaximin

Linaclotide

Others

By End User

Drug Stores & Retail Pharmacies

Hospitals Pharmacies

Online Pharmacies

Competitive Scenario

The study looks at the top companies' market competitiveness, as well as their biographies, market prices, and channel characteristics. A comprehensive market analysis takes into account a variety of factors, including a country's demographic and business cycles, as well as market-specific microeconomic ramifications. The analysis discovered a shift in market paradigms in terms of regional competitive advantage and the competitive landscape of important enterprises. Product line expansion, mergers and acquisitions, agreements, regional expansion, and collocation have all been used by players to increase Irritable Bowel Syndrome Treatment Market market penetration and reinforce their positions.

Key Questions Answered in the Irritable Bowel Syndrome Treatment Market Report

What are the major global commercial ramifications of the COVID-19 pandemic?

What are the current market drivers and restraints? What effect will future incentives and limits have?

What is the global market's rate of expansion? What will the future growth pattern be?

What are the main trends and where can you find them? In each region, what are the primary revenue pockets for market expansion?

About Us

SNS Insider is a market research and insights firm that has won several awards and earned a solid reputation for service and strategy. We are a strategic partner who can assist you in reframing issues and generating answers to the trickiest business difficulties. For greater consumer insight and client experiences, we leverage the power of experience and people.

When you employ our services, you will collaborate with qualified and experienced staff. We believe it is crucial to collaborate with our clients to ensure that each project is customized to meet their demands. Nobody knows your customers or community better than you do. Therefore, our team needs to ask the correct questions that appeal to your audience in order to collect the best information.

Related Reports

Patient Portal Market Analysis

Plasma Therapy Market Analysis

Preeclampsia Diagnostics Market Analysis

Serum free Media Market Analysis

Glaucoma Therapeutics Market Analysis

[spookysaladchaos]

Global Top 3 Companies Accounted for 81% of total Irritable Bowel Syndrome (IBS) market (QYResearch, 2021)

Irritable bowel syndrome (IBS) is a common disorder that affects the large intestine. Signs and symptoms include cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both. IBS is a chronic condition that need to manage long term.

IBS that causes increased diarrhea is often called IBS-D. Diarrhea predominant irritable bowel syndrome (IBS-D) is a subtype of IBS in which a person experiences frequent episodes of diarrhea with accompanying abdominal pain. Like IBS, IBS-D is a functional gastrointestinal disorder (FGD) in that there is no visible disease, inflammation, or injury to account for its symptoms. It is estimated that approximately a third of people who have IBS experience the disorder with diarrhea as the predominant bowel habit.

In this report, we study the drugs for diarrhea predominant irritable bowel syndrome (IBS-D).

According to the new market research report “Global Irritable Bowel Syndrome (IBS) Market Report 2023-2029”, published by QYResearch, the global Irritable Bowel Syndrome (IBS) market size is projected to reach USD 3.27 billion by 2029, at a CAGR of 12.0% during the forecast period.

Figure.   Global Irritable Bowel Syndrome (IBS) Market Size (US$ Million), 2018-2029

Based on or includes research from QYResearch: Global Irritable Bowel Syndrome (IBS) Market Report 2023-2029.

Figure.   Global Irritable Bowel Syndrome (IBS) Top 6 Players Ranking and Market Share（Based on data of 2021, Continually updated）

Based on or includes research from QYResearch: 2021 data information of Global Irritable Bowel Syndrome (IBS) Market Report 2023-2029.

The global key manufacturers of Irritable Bowel Syndrome (IBS) include Bausch Health, Allergan, etc. In 2020, the global top three players had a share approximately 81.0% in terms of revenue.

About QYResearch

QYResearch founded in California, USA in 2007.It is a leading global market research and consulting company. With over 16 years’ experience and professional research team in various cities over the world QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and customized research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services, good corporate citizenship, and our strong commitment to sustainability. Up to now, we have cooperated with more than 60,000 clients across five continents. Let’s work closely with you and build a bold and better future.

QYResearch is a world-renowned large-scale consulting company. The industry covers various high-tech industry chain market segments, spanning the semiconductor industry chain (semiconductor equipment and parts, semiconductor materials, ICs, Foundry, packaging and testing, discrete devices, sensors, optoelectronic devices), photovoltaic industry chain (equipment, cells, modules, auxiliary material brackets, inverters, power station terminals), new energy automobile industry chain (batteries and materials, auto parts, batteries, motors, electronic control, automotive semiconductors, etc.), communication industry chain (communication system equipment, terminal equipment, electronic components, RF front-end, optical modules, 4G/5G/6G, broadband, IoT, digital economy, AI), advanced materials industry Chain (metal materials, polymer materials, ceramic materials, nano materials, etc.), machinery manufacturing industry chain (CNC machine tools, construction machinery, electrical machinery, 3C automation, industrial robots, lasers, industrial control, drones), food, beverages and pharmaceuticals, medical equipment, agriculture, etc.

[techninja]

Irritable Bowel Syndrome Treatment Market Is Estimated To Witness High Growth Owing To Increasing Prevalence of IBS

The Irritable Bowel Syndrome Treatment market is estimated to be valued at US$ 1,635.40 Mn in 2023 and is expected to exhibit a CAGR of 13.% over the forecast period from 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: Irritable bowel syndrome (IBS) is a chronic condition that causes abdominal pain and changes in bowel habits. Symptoms usually include abdominal pain and either diarrhea, constipation, or both. IBS treatment aims to manage symptoms through lifestyle changes and medications. Common IBS treatments include antidiarrheals, antispasmodics, antidepressants, bile acid sequestrants, and probiotics. Market Dynamics: Two key factors driving growth of the irritable bowel syndrome treatment market include rising prevalence of IBS worldwide and growing adoption of prescribed drugs for IBS management. According to the International Foundation for Gastrointestinal Disorders, IBS affects 25 million people in the United States annually. Stress, diet changes, antibiotic use, and food sensitivities can trigger IBS symptoms. With increasing stress levels and lifestyle changes globally, the prevalence of IBS is steadily rising. Furthermore, while lifestyle changes and probiotics remain first line treatments for mild IBS cases, more severe cases are increasingly being managed through prescription drugs like antispasmodics and antidepressants. This is expected to boost the demand for prescribed IBS treatments over the forecast period. SWOT Analysis Strengths: Irritable bowel syndrome treatment market has strong growth potential due to the rising prevalence of IBS. Various treatment options available to manage the symptoms of IBS effectively. Growing awareness regarding IBS and its treatment options among patients and physicians. Weaknesses: High cost associated with IBS treatment limits revenue growth potential. Lack of approved drugs for complete cure of IBS poses major challenge. Opportunities: Emergence of pipeline drugs in clinical trials offers lucrative opportunities. Rising healthcare expenditures in emerging nations provide new opportunities. Threats: Patent expiration of blockbuster drugs affects market revenue. Stringent regulatory approval process for new drugs. Key Takeaways: The global Irritable Bowel Syndrome Treatment market is expected to witness high growth, exhibiting 13% CAGR over the forecast period, due to increasing prevalence of Irritable Bowel Syndrome globally. As per reports, around 10-15% of adult population suffer from IBS resulting in increasing demand for effective treatment options. Regional analysis: North America holds largest share in global irritable bowel syndrome treatment market due to growing acknowledgment and diagnosis of IBS. Favourable reimbursement policies and technological advancements also contribute to market growth. Asia Pacific exhibits fastest growth due rising healthcare expenditures and large patient pool. Improving access to healthcare in developing nations presents growth opportunities. Key players operating in the Irritable Bowel Syndrome Treatment market are Abbott, Synergy Pharma, Mallinckrodt, Bausch Health Companies Inc., Ardelyx, Astellas Pharma Inc., Novartis AG, GSK plc., Ironwood Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited. Key players focus on new drug development and acquisitions to strengthen market position.

[meghanester]

Irritable Bowel Syndrome Drugs Market 2023 – 2035 Growth to Witness a Surge by Rise in Prevalence of the Disease with a Notable CAGR.

Research Nester published a report titled “Irritable Bowel Syndrome Drugs Market: Global Demand Analysis & Opportunity Outlook 2035” which delivers detailed overview of the irritable bowel drugs market in terms of market segmentation by type, by product, by end user and by region.

Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.

The irritable bowel syndrome drug market is anticipated to record a significant CAGR over the forecast period, i.e., 2023 – 2035, owing to the rising geriatric population, increase in the occurrence of gastrointestinal disorders, growing stress levels of people globally, and unhealthy eating habits. Additionally, escalating advertising campaigns for the treatment of gastrointestinal disorders and increasing usage of over the counter drugs that relieve the symptoms of IBS are other reasons contributing to market growth in the coming years.

The market is segmented by type into IBS with diarrhea (IBS-D), IBS with constipation (IBS-C) and mixed IBS (IBS-M), out of which IBS with diarrhea (IBS-D) segment is predicted to hold leading share in the irritable bowel syndrome drugs market on account of rising cases of gastrointestinal disorders such as constipation and diarrhea owing to sedentary lifestyle and increased intake of medications such as linaclotide and lubiprostone worldwide.

Download Sample of This Strategic Report: https://www.researchnester.com/sample-request-3040

The irritable bowel syndrome drug market is segmented into five main regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The North American region holds the largest market share owing to the availability of cheap fast food and sedentary lifestyle changes of the population. On the other hand, Asia-Pacific is expected to witness the highest growth during the forecast period on the back of rise in the number of hospitals equipped with specialist surgical services, and growing advancements in healthcare technology.

Growth in the Prevalence of Irritable Bowel Syndrome to Boost Market Growth

As a result of increasing trend of sedentary lifestyle patterns, there has been a hike in the number of cases reporting gastrointestinal disorders which further trigger irritable bowel syndrome. This has led to the production of new drugs, which are symptom specific, by key market players, which in turn is anticipated to fuel the growth of the market over the forecast period.

“The Final Report will cover the impact analysis of COVID-19 on this industry.”

Request for customization @ https://www.researchnester.com/customized-reports-3040

However, growing completion among major market players is expected to operate as key restraint to the growth of irritable bowel syndrome drugs market in the near future.

This report also provides the existing competitive scenario of some of the key players of the irritable bowel syndrome drugs market which includes company profiling of Abbott Services (NYSE: ABT), Ardelyx, Inc. (NASDAQ: ARDX), Astellas Pharma Inc (TYO: 4503), AstraZeneca (LON: AZN), GlaxoSmithKline Plc (LON: GSK), Johnson & Johnson Services, Inc. (NYSE: JNJ), Novartis AG (SWX: NOVN), Ironwood Pharmaceuticals, Inc (NASDAQ: IRWD), Synergy Pharma Consultancy Private Limited, Synthetic Biologics, Inc (NYSEAMERICAN: SYN), and others. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global irritable bowel syndrome drugs market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.     

Access Our Report at:

About Research Nester

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties.

Contact for more Info:

AJ Daniel

Email: info@researchnester.com

U.S. Phone: +1 646 586 9123

U.K. Phone: +44 203 608 5919

[health-views-updates]

The Future of the Digestive Health Market: Key Trends and Projections

Digestive Health Market Outlook, Scope & Overview:

Industry reports indicate that the global digestive health market was valued at USD 46.08 billion in 2023 and is projected to reach USD 89.81 billion by 2031, growing at a CAGR of 8.7% over the forecast period 2024-2031.

Technological Advancements to Drive Growth of Global Digestive Health Market

The adoption of advanced digestive health solutions will continue to influence global market revenues. Healthcare providers and consumers are increasingly focusing on digestive health due to its critical role in overall well-being and disease prevention.

As a product segment, probiotics currently hold a significant share of the global digestive health market. This segment is anticipated to grow at a year-over-year rate of 8.7% in 2024 over 2023 and reach USD 89.81 billion in revenues by 2031. The increasing awareness of gut health, coupled with advancements in digestive health products, is expected to drive market growth.

Get a Free Sample Report: https://www.snsinsider.com/sample-request/3134

Digestive Health Solutions – Market Dynamics

Drivers:

Digestive health solutions are witnessing significant growth in the global market due to their ability to improve gut health, enhance nutrient absorption, and prevent gastrointestinal disorders. The growing prevalence of digestive health issues, such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), coupled with the increasing consumer demand for natural and functional foods, are key factors driving the adoption of digestive health solutions worldwide. Additionally, the rising trend of preventive healthcare and the increasing availability of over-the-counter digestive health products are further propelling market growth.

Restraints:

Despite the growth potential, challenges such as the high cost of advanced digestive health products, regulatory hurdles, and the lack of consumer awareness in certain regions are hindering the widespread adoption of digestive health solutions. Moreover, the variability in product efficacy and the need for rigorous scientific validation pose additional challenges to market expansion.

Digestive Health Solutions – Market Outlook

The proven benefits of digestive health solutions in improving overall health, preventing digestive disorders, and enhancing quality of life have contributed to the market's growth. Digestive health solutions are expected to witness increased adoption across major markets, including North America, Europe, and Asia Pacific, driven by advancements in product formulations and the growing focus on gut health.

Global Digestive Health Market

The rise in demand for digestive health solutions in developed and emerging markets is expected to drive market growth over the forecast period. North America currently holds a significant market share in the global digestive health market, with the US being a key contributor to market revenues. Europe and Asia Pacific regions are also experiencing rapid adoption of digestive health solutions, supported by increasing consumer health awareness and investments in research and development.

Key Players in the Digestive Health Solutions Market

Leading companies in the digestive health solutions market include Nestlé Health Science, Danone, Abbott Laboratories, and Bayer AG. These companies are at the forefront of developing and commercializing advanced digestive health products for various applications, including probiotics, prebiotics, digestive enzymes, and dietary supplements.

In conclusion, the global digestive health market is poised for substantial growth over the forecast period, driven by technological advancements, increasing consumer awareness, and the expanding adoption of digestive health solutions across diverse healthcare and wellness settings.

Other Trending Reports

Over-The-Counter Drugs Industry Growth

Medical Terminology Software Industry Growth

Analgesics Industry Growth

Vitrectomy Devices Industry Growth

[cavixorg]

A biopharmaceutical business called Ardelyx, Inc. finds, creates, and sells drugs for digestive and cardiorenal therapeutic categories both domestically and abroad. Tenapanor, the company's leading product candidate, has successfully completed a Phase II clinical court case. For the treatment of individuals with constipation-related irritable bowel syndrome. And is currently undergoing a Phase II clinical trial to manage hyperphosphatemia in adult individuals suffering from chronic kidney disease (CKD) who are receiving dialysis. It is also producing RDX020, an initial program on metabolic acidosis, a significant electrolyte issue in individuals with CKD, and RDX013, synthetic potassium secretagogue, again for treatment of increased serum potassium, called hyperkalemia, a concern among some patients with renal. Where And When Was Ardelyx Founded? For the development and marketing of tenapanor in their respective markets, the business has partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Heavy Industry Co. Ltd. in China. And Knight Therapeutics, Inc. in Canada. In June 2008, the organization's name was changed from Nteryx, Inc. to Ardelyx, Inc. Waltham, Massachusetts serves as the corporate headquarters for Ardelyx, Inc., which was founded in 2007. Who Are The Principal Shareholders In Ardelyx? Numerous institutional and individual investors hold shares of Ardelyx. Vanguard Group Inc. (3,06%), Point72 Asset Management L.P. (0,99%), BlackRock Inc. (0.81%), Boothbay Fund Management LLC (0.25%), Prosight Management LP (0.60%), State Street Corp (0.22%) are the top institutional shareholders. David M. Mott, David P. Rosenbaum, Elizabeth A. Grammer, Forest Baskett, Jeffrey W. Jacobs, Justin A. Renz, Michael Raab, Robert Blanks, Scott D. Sandell, and Susan Rodriguez are among the insiders that have equity in the company. What The Other Stocks Do Ardelyx Shareholders Own? Several companies that other Ardelyx investors own are Micron Technology (MU), TherapeuticsMD (TXMD), Rigel Pharmaceuticals (RIGL), NVIDIA (NVDA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), and Advanced Micro Devices, Corbus Pharmaceuticals (CRBP), according to aggregate data from MarketBeat watchlists (AMD). Do Investors Short The Stock Ardelyx? October saw a decline in short interest for Ardelyx. On October 31st, there were 7,340,000 shares total in short interest, which is a 7.6% decline from the total of 7,940,000 ARDX stock on October 15th. The days-to-cover percentage is currently 2.1 days assuming an average trading activity of 3,520,000 shares. Historical Price & Market Analysis For ARDX ARDX stock is presently ranked #1337 among all cryptocurrencies with an ARDX stock price of $0.003801. With 277,807,957 coins in circulation and a $1,056,065 market cap, ARDX is now in circulation. The cost of ARDX has dropped by 13.97% over the last day. The past week has been difficult for ARDX as it has down 0.21%. If you are considering purchasing ARDX, now may be a right idea to invest as ARDX stock is displaying bearish indicators this week. The value of ARDX decreased by 13.18% during the past 30 days, dropping from its original level of $0.004379 to $0.000577. Due to the current decline, ARDX is currently experiencing a dip. Is It Time To Buy As Well As Sell Ardelyx Stock At The Moment? Under the ticker "ARDX," Ardelyx is traded on the NASDAQ. In the past year, Ardelyx has received "hold," "buy," as well as "sell" ratings from 6 Wall Street securities research analysts. 4 buy ratings and 2 hold ratings are both now present for the stock. Analysts covering Wall Street equities agree that investors ought to "buy" ARDX shares. What Is The Current Stock Price Of Ardelyx? At the time of writing, one unit of ARDX stock price roughly $1.80. The market value of Ardelyx (NASDAQ:ARDX) is $331.80 million, and its annual revenue is $10.10 million. The biopharmaceutical company generates net income (profit) of $-158,160,000.

00 annually, or ($0.85) per share. The ARDX stock price at the beginning of the year was $1.10. Since then, the ARDX stock price has climbed by 60.9% to $1.80. On Monday, February 27, 2023, the business is set to announce its upcoming quarterly profits. What Are The Consensus Ratings And Ardelyx Stock Price? Given the current 2 keep rating and 4 buy recommendations for ARDX, the consensus recommendation for Ardelyx stock based on the ratings issued by 6 analysts in the previous year is Moderate Buy. With a high ARDX stock price objective of $10.00 as well as a low cost target of $1.00, the average Ardelyx twelve-month ARDX stock price forecast is $5.17. Analysts upgraded Ardelyx's stock once in the past ninety days. Based on analysts' 12-month ARDX stock price forecast, the stock of Ardelyx is expected to rise by 425.21%. Are Wall Street Analysts More Favorable Toward Ardelyx Than Their Rivals? Ardelyx is favored by analysts over other medical companies. While the overall opinion rating for medical businesses is Buy, Ardelyx's rating is Moderate Buy. ARDX stock price is preferred by MarketBeat users over other Medical businesses. ARDX stock price forecast had an outperform vote from 68.04% of MarketBeat users, compared to an average of 66.40% for medical firms. How Can I Get Ardelyx Stock? Proceed to checkout after entering the amount you wish to invest into ARDX stock price. Instead of buying the whole part, which can be much more expensive, lets you buy fractional shares, which are smaller, more cheap parts of investments. Within only a few minutes, choose a strategy and set up the investment portfolio. Your shares of Ardelyx Inc will be added in your personal portfolio once your account is complete. You will become a shareholder in Ardelyx Inc. once the market order for ARDX stock has been fulfilled. How Soon Should One Start Investing? Generally speaking, you can accumulate more wealth the sooner you start investing. How? The effectiveness of compounding. Consider investing $100 and receiving a 5% return each year. You would make $5 in the first year. The next year, after reinvesting those profits, you would receive interest on $105 for a profit of $5.25. Your balance and the return on the that balance both rise each time you reinvest money that you make. The effect increases as your money compounds over time. Consider starting with $100 and making $25 a quarter for 20 years at an annualized level of 5%. You would have made a deposit of $6,100 and you balance would've been over $10,000 after 20 years. Evaluating Your Level Of Risk Aversion All investments carry ARDX stock price prediction, which includes the possibility of financial loss. However, each person's comfort level with risk varies greatly. Your age, income, allocation of resources necessary, and other variables come into play. Investors often categorize risk appetite into three groups: Conservative. A cautious investor prefers stability to the possibility of greater rewards. 40% equities and 60% bonds are anticipated to make up the asset allocation. Moderate. Moderate investors try to strike a balance between security and greater profit possibilities. Usually, they divide their budget between 60% equities and 40% bonds. Aggressive. Investors who are aggressive aren't afraid to take huge chances in the hopes of getting great returns. Typically, they invest 80% in equities and 20% in bonds. How Much Is The ARDX Stock Currently Worth? ARDX stock (NASDAQ) There are now 187,459,645 shares of Ardelyx outstanding. The market capitalization ARDX stock price forecast of Ardelyx stock, which is currently selling at $1.77 per piece, is $331.80M. On June 19, 2014, Ardelyx stock went public at a price of $14.11. Your return over the last eight years would be -87.46%, for an annualized return of -22.86%, if you had purchased Ardelyx shares at $14.11. Price Predictions For ARDX Bearish indicators have been present during the past seven days for ARDX as the coin fell 0.

21%. As a result, we anticipate a minor recovery over the course of the following week as investors acquire ARDX stock at a discount. The ARDX stock price immediate, daily, weekly, and yearly ARDX stock price prediction are displayed below. This ARDX stock price forecast aims to provide you with an idea of what ARDX would be worth in an hour, today, next, over the following week, and over the following month. What Is The Anticipated Stock Price For Ardelyx In 2023? For the stock of Ardelyx, 6 equity research analysts have provided 12-month price targets. Their predictions for the price of ARDX stock range from $1 to $10. They predict that during the next year, the current share price will rise on average to $5.17. This indicates a potential gain of 191.9% over the stock's present price. ARDX stock price prediction The 52-week high and low of Ardelyx were $2.19 and $0.49, respectively. Right now, ARDX stock price prediction is 261.22% away from its 52-week low and -19.18% away from its 52-week high. ARDX Stock Forecast 2024 The anticipate ARDX stock price will grow significantly in 2024 as cryptocurrency becomes more popular across a wide range of industries. The price might therefore increase to $0.014445, average at $0.013305. A price of $0.012165 could be the minimum for ARDX stock. ARDX Stock Forecast 2025 The ARDX stock price prediction might reach a maximum of $0.018247 with an average cost of $0.017106 in 2025 if the amount of cash invested in the cryptocurrency market keeps increasing. If a sell-off takes place, $0.015966 is the lowest price we anticipate. ARDX Stock Forecast 2026 The acceptance of ARDX stock by nations around the world suggests that the ARDX stock price might reach a maximum of $0.022048 by 2026, with an average cost of $0.020908 anticipated. Additionally, $0.019767 might be the minimal price for that year. ARDX Stock Forecast 2027 The ARDX stock price prediction will increase in 2027 as policymakers begin to acknowledge that ARDX stock price forecast are here to stay. By 2027, investors may ARDX stock price prediction to trade at a high price of $0.02585 and a minimum cost of $0.023569. The anticipated average cost for 2027 is $0.024709. ARDX Stock Forecast 2028 Due to the ARDX stock price prediction over the last five years, 2028 will see another significant bull, which could cause ARDX stock investors to see ARDX reach a top price of $0.029651 before averaging $0.028511. Our technical analysis ARDX stock price forecast a minimum price of $0.02737. ARDX Stock Forecast 2029 Based on the current state of the market, ARDX is anticipated to continue rising reaching $0.033453 in 2029. If this support is not obtained, ARDX stock price forecast may trend around $0.032312 as well as bottom out and at $0.031172. ARDX Stock Forecast 2030 For ARDX stock price forecast, this year will go down in history. In 2030, we anticipate that ARDX will hit a new All Time High of $0.037254, while the new price cap of ArdCoin may be $0.034973. In the worst possible scenario, ARDX stock price forecast closes out 2030 trading at $0.036114. What Kind Of Investment Do You Really Need To Make? Contrary to popular belief, starting an investment doesn't require a sizable chunk of money. In fact, you may frequently start off with just a $1. Although stock shares and other securities might be expensive, many brokerages provide fractional shares that allow you to buy them in smaller amounts. Some also provide accounts with low or no fees. If you decide to invest, you should continue to contribute funds to your accounts. Particularly if you have lengthy objectives like retirement. Many experts advise consistently investing 10–20 percent of your salary. For instance, the 50/30/20 budgeting strategy allots roughly 20% of your budget for savings and investments. Investment Styles: Active Vs. Passive Investors that are hands-on and active prefer to concentrate upon short-term ARDX stock price prediction. they typically invest a lot of time in maintaining the portfolios and trade less frequently.

Active stock market participants may also attempt to outperform the market by selecting particular ARDX stock price prediction that may beat benchmark indices such as the S&P 500. But even experienced fund managers can't consistently outperform the market. The higher risk and higher fees associated with productive investments can be attributed to how frequently it trades. A purchase investment strategy is typically used by passive, hands-off investors.